BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 8662951)

  • 1. Functional analysis of the cellular receptor for urokinase in plasminogen activation. Receptor binding has no influence on the zymogenic nature of pro-urokinase.
    Ellis V
    J Biol Chem; 1996 Jun; 271(25):14779-84. PubMed ID: 8662951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kinetics of reciprocal pro-urokinase/plasminogen activation--stimulation by a template formed by the urokinase receptor bound to poly(D-lysine).
    Petersen LC
    Eur J Biochem; 1997 Apr; 245(2):316-23. PubMed ID: 9151959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Receptor-mediated regulation of plasminogen activator function: plasminogen activation by two directly membrane-anchored forms of urokinase.
    Vines DJ; Lee SW; Dichek DA; Ellis V
    J Pept Sci; 2000 Sep; 6(9):432-9. PubMed ID: 11016879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of purified, soluble urokinase receptor on the plasminogen-prourokinase activation system.
    Behrendt N; Danø K
    FEBS Lett; 1996 Sep; 393(1):31-6. PubMed ID: 8804418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A competitive chromogenic assay to study the functional interaction of urokinase-type plasminogen activator with its receptor.
    Rettenberger P; Wilhelm O; Oi H; Weidle UH; Goretzki L; Koppitz M; Lottspeich F; König B; Pessara U; Kramer MD
    Biol Chem Hoppe Seyler; 1995 Oct; 376(10):587-94. PubMed ID: 8590627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasminogen activation by pro-urokinase in complex with its receptor--dependence on a tripeptide (Spectrozyme plasmin).
    Wang J; Mazar A; Quan N; Schneider A; Henkin J
    Eur J Biochem; 1997 Jul; 247(1):256-61. PubMed ID: 9249034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assembly of urokinase receptor-mediated plasminogen activation complexes involves direct, non-active-site interactions between urokinase and plasminogen.
    Ellis V; Whawell SA; Werner F; Deadman JJ
    Biochemistry; 1999 Jan; 38(2):651-9. PubMed ID: 9888805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maspin retards cell detachment via a novel interaction with the urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor system.
    Yin S; Lockett J; Meng Y; Biliran H; Blouse GE; Li X; Reddy N; Zhao Z; Lin X; Anagli J; Cher ML; Sheng S
    Cancer Res; 2006 Apr; 66(8):4173-81. PubMed ID: 16618739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inactivation of receptor-bound pro-urokinase-type plasminogen activator (pro-uPA) by thrombin and thrombin/thrombomodulin complex.
    Wilhelm S; Wilhelm O; Schmitt M; Graeff H
    Biol Chem Hoppe Seyler; 1994 Sep; 375(9):603-8. PubMed ID: 7840902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specific inhibition of the activity of the urokinase receptor-mediated cell-surface plasminogen activation system by suramin.
    Ellis V; Danø K
    Biochem J; 1993 Dec; 296 ( Pt 2)(Pt 2):505-10. PubMed ID: 8257443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct interaction of the kringle domain of urokinase-type plasminogen activator (uPA) and integrin alpha v beta 3 induces signal transduction and enhances plasminogen activation.
    Tarui T; Akakura N; Majumdar M; Andronicos N; Takagi J; Mazar AP; Bdeir K; Kuo A; Yarovoi SV; Cines DB; Takada Y
    Thromb Haemost; 2006 Mar; 95(3):524-34. PubMed ID: 16525582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
    Magdolen V; Bürgle M; de Prada NA; Schmiedeberg N; Riemer C; Schroeck F; Kellermann J; Degitz K; Wilhelm OG; Schmitt M; Kessler H
    Biol Chem; 2001 Aug; 382(8):1197-205. PubMed ID: 11592401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ligand binding regions in the receptor for urokinase-type plasminogen activator.
    Liang OD; Chavakis T; Kanse SM; Preissner KT
    J Biol Chem; 2001 Aug; 276(31):28946-53. PubMed ID: 11501527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell-surface acceleration of urokinase-catalyzed receptor cleavage.
    Høyer-Hansen G; Ploug M; Behrendt N; Rønne E; Danø K
    Eur J Biochem; 1997 Jan; 243(1-2):21-6. PubMed ID: 9030717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pro-urokinase plasminogen-activation system in the presence of serpin-type inhibitors and the urokinase receptor: rescue of activity through reciprocal pro-enzyme activation.
    Behrendt N; List K; Andreasen PA; Danø K
    Biochem J; 2003 Apr; 371(Pt 2):277-87. PubMed ID: 12534347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of the interaction of urokinase-type plasminogen activator (uPA) with its receptor (uPAR) by synthetic peptides.
    Bürgle M; Koppitz M; Riemer C; Kessler H; König B; Weidle UH; Kellermann J; Lottspeich F; Graeff H; Schmitt M; Goretzki L; Reuning U; Wilhelm O; Magdolen V
    Biol Chem; 1997; 378(3-4):231-7. PubMed ID: 9165076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness.
    Holst-Hansen C; Johannessen B; Høyer-Hansen G; Rømer J; Ellis V; Brünner N
    Clin Exp Metastasis; 1996 May; 14(3):297-307. PubMed ID: 8674284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Binding of human urokinase-type plasminogen activator to its receptor: residues involved in species specificity and binding.
    Quax PH; Grimbergen JM; Lansink M; Bakker AH; Blatter MC; Belin D; van Hinsbergh VW; Verheijen JH
    Arterioscler Thromb Vasc Biol; 1998 May; 18(5):693-701. PubMed ID: 9598826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Photoaffinity labeling of the human receptor for urokinase-type plasminogen activator using a decapeptide antagonist. Evidence for a composite ligand-binding site and a short interdomain separation.
    Ploug M; Ostergaard S; Hansen LB; Holm A; Danø K
    Biochemistry; 1998 Mar; 37(11):3612-22. PubMed ID: 9521680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of the tumor-associated urokinase-type plasminogen activation system: effects of high-level synthesis of soluble urokinase receptor in ovarian and breast cancer cells in vitro and in vivo.
    Magdolen V; Krüger A; Sato S; Nagel J; Sperl S; Reuning U; Rettenberger P; Magdolen U; Schmitt M
    Recent Results Cancer Res; 2003; 162():43-63. PubMed ID: 12790320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.